{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:14:59Z","timestamp":1793088899563,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012239","name":"Hubei Technological Innovation Special Fund","doi-asserted-by":"publisher","award":["2019ACA132"],"award-info":[{"award-number":["2019ACA132"]}],"id":[{"id":"10.13039\/501100012239","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2020CFB805"],"award-info":[{"award-number":["2020CFB805"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.neurot.2024.e00345","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T04:27:20Z","timestamp":1710476840000},"page":"e00345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness analysis of three-drug combination therapies for refractory focal epilepsy"],"prefix":"10.1016","volume":"21","author":[{"given":"Chunmei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2024.e00345_bib1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2024.e00345_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ana.21064","article-title":"Results of treatment changes in patients with apparently drug-resistant chronic epilepsy","volume":"62","author":"Luciano","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00345_bib3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/jnnp-2011-302085","article-title":"Treatment changes in a cohort of people with apparently drug-resistant epilepsy: an extended follow-up","volume":"83","author":"Neligan","year":"2012","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2024.e00345_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1528-1167.2008.01866.x","article-title":"Lamotrigine-valproic acid combination therapy for medically refractory epilepsy","volume":"50","author":"Moeller","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurot.2024.e00345_bib5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/seiz.2002.0711","article-title":"Seizure freedom with more than one antiepileptic drug","volume":"11","author":"Stephen","year":"2002","journal-title":"Seizure"},{"key":"10.1016\/j.neurot.2024.e00345_bib6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.eplepsyres.2011.09.008","article-title":"Antiepileptic drug combinations--have newer agents altered clinical outcomes?","volume":"98","author":"Stephen","year":"2012","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurot.2024.e00345_bib7","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1157.1999.tb00832.x","article-title":"The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction","volume":"40","author":"Pisani","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurot.2024.e00345_bib8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(05)60613-7","article-title":"Lamotrigine and topiramate may be a useful combination","volume":"351","author":"Stephen","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2024.e00345_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejphar.2013.10.063","article-title":"Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model - a type II isobolographic analysis","volume":"723","author":"Florek-Luszczki","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neurot.2024.e00345_bib10","first-page":"379","article-title":"Seizure control with antiepileptic\u00a0drug\u00a0therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre","volume":"14","author":"Steinhoff","year":"2012","journal-title":"Epileptic\u00a0Disord"},{"key":"10.1016\/j.neurot.2024.e00345_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.0b013e31823ed0dd","article-title":"Comparative efficacy of combination drug therapy in refractory epilepsy","volume":"78","author":"Poolos","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00345_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eplepsyres.2018.03.011","article-title":"Comparative efficacy of unique antiepileptic drug regimens in focal epilepsy: an exploratory study","volume":"142","author":"Legge","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurot.2024.e00345_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14737175.2020.1707668","article-title":"The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection","volume":"20","author":"Verrotti","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.neurot.2024.e00345_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40263-017-0471-7","article-title":"Selecting rational drug combinations in epilepsy","volume":"31","author":"Abou-Khalil","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurot.2024.e00345_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","article-title":"Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis","volume":"82","author":"Lattanzi","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2024.e00345_bib16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurot.2024.e00345_bib17","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","article-title":"Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"99","author":"Klein","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00345_bib18","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s10072-020-04636-7","article-title":"Perampanel as first add-on choice on the treatment of mesial temporal lobe epilepsy: an observational real-life study","volume":"42","author":"Labate","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurot.2024.e00345_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1528-1167.2010.02520.x","article-title":"Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy","volume":"51","author":"Canevini","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurot.2024.e00345_bib20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1528-1157.1997.tb01142.x","article-title":"Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects","volume":"38","author":"Deckers","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurot.2024.e00345_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/14737175.6.3.397","article-title":"Refractory epilepsy: mechanisms and solutions","volume":"6","author":"Kwan","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.neurot.2024.e00345_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurot.2024.e00345_bib23","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2165\/00003495-200666140-00004","article-title":"Combination therapy in epilepsy: when and what to use","volume":"66","author":"Kwan","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2024.e00345_bib24","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S1474-4422(23)00151-5","article-title":"Drug resistance in epilepsy","volume":"22","author":"Perucca","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00345_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/brain\/awh682","article-title":"Molecular and cellular mechanisms of pharmacoresistance in epilepsy","volume":"129","author":"Remy","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00345_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurot.2024.e00345_bib27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.seizure.2009.06.009","article-title":"Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model","volume":"18","author":"Dudra-Jastrzebska","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.neurot.2024.e00345_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eplepsyres.2009.06.003","article-title":"Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model","volume":"86","author":"Wojda","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurot.2024.e00345_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11278","article-title":"Assessment of potential drug-drug interactions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study)","volume":"8","author":"Patel","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.neurot.2024.e00345_bib30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/jpet.103.054197","article-title":"Interaction of antiepileptic drugs with human P-glycoprotein in vitro","volume":"307","author":"Weiss","year":"2003","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.neurot.2024.e00345_bib31","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1007\/s11095-009-9961-8","article-title":"The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins","volume":"26","author":"Luna-Tort\u00f3s","year":"2009","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.neurot.2024.e00345_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17994-3","article-title":"Efflux dynamics of the antiseizure drug, levetiracetam, through the P-glycoprotein channel revealed by advanced comparative molecular simulations","volume":"12","author":"Behmard","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2024.e00345_bib33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1528-1167.2006.00414.x","article-title":"Influence of lamotrigine and topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy","volume":"47","author":"Wang-Tilz","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurot.2024.e00345_bib34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/0333102416683925","article-title":"Antiepileptic drugs in migraine and epilepsy: who is at increased risk of adverse events?","volume":"38","author":"Romoli","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurot.2024.e00345_bib35","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1528-1157.1999.tb00831.x","article-title":"Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group","volume":"40","author":"Faught","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurot.2024.e00345_bib36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and epilepsy: definitions proposed by the international League against epilepsy (ILAE) and the international bureau for epilepsy (IBE)","volume":"46","author":"Fisher","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurot.2024.e00345_bib37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.seizure.2018.06.002","article-title":"The quality of life of older adults with epilepsy: a systematic review","volume":"60","author":"Baranowski","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.neurot.2024.e00345_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.seizure.2006.10.011","article-title":"Factors influencing on quality of life in people with epilepsy","volume":"16","author":"Guekht","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.neurot.2024.e00345_bib39","first-page":"Cd010961","article-title":"Perampanel add-on for drug-resistant focal epilepsy","volume":"4","author":"Bresnahan","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurot.2024.e00345_bib40","doi-asserted-by":"crossref","first-page":"e1376","DOI":"10.1212\/WNL.0000000000206776","article-title":"Safety, efficacy, and tolerability of modified atkins diet in persons with drug-resistant epilepsy: a randomized controlled trial","volume":"100","author":"Manral","year":"2023","journal-title":"Neurology"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792400031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792400031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T17:18:08Z","timestamp":1742318288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792400031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S187874792400031X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00345","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness analysis of three-drug combination therapies for refractory focal epilepsy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00345"}}